These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Health-related quality of life in men with metastatic castration-resistant prostate cancer. Gee A; Challapalli A; Bahl A Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):941-9. PubMed ID: 26512743 [TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer. Armstrong AJ Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272 [No Abstract] [Full Text] [Related]
5. Update of the Andalusian Association of Urology protocol for the management of metastatic castration-resistant prostate cancer. Álvarez-Ossorio JL; Cozar-Olmo JM; Juárez-Soto Á; Medina-López R; Moreno-Jiménez J; Requena-Tapia MJ Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):125-130. PubMed ID: 32081443 [No Abstract] [Full Text] [Related]
6. Screening of visceral metastasis in castration-resistant prostate cancer: a cornerstone in personalized patient's care. Grobet-Jeandin E; Valerio M Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):3-4. PubMed ID: 36203050 [No Abstract] [Full Text] [Related]
7. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758 [TBL] [Abstract][Full Text] [Related]
8. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer. Tsao CK; Galsky MD; Oh WK Eur Urol; 2014 Aug; 66(2):184-5. PubMed ID: 24433812 [TBL] [Abstract][Full Text] [Related]
9. Current, new and novel therapy for castration-resistant prostate cancer. Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660 [TBL] [Abstract][Full Text] [Related]
10. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. Li J; Armstrong AJ Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773 [No Abstract] [Full Text] [Related]
11. Continuous, comprehensive and crucial care: The role of the CNS in the metastatic castration-resistant prostate cancer patient pathway. Basketter V; Benney M; Causer L; Fleure L; Hames D; Jones S; Patel K; White L Br J Nurs; 2018 Feb; 27(Sup4b):S1-S8. PubMed ID: 29461871 [TBL] [Abstract][Full Text] [Related]
12. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer. Dreicer R Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772 [No Abstract] [Full Text] [Related]
13. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer? Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852 [TBL] [Abstract][Full Text] [Related]